Table of Contents | --- | |-------| | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | |--------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------| | 50 Health Sciences Drive, Stony Brook, New York | 11790 | (631) 240-8800 | | (Address of principal executive offices) | (Zip Code) Securities registered pursuant to Section 12(b) of t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Registrant's telephone number, including area code: (952) 456-5300 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from to Commission file number: 001-41039 PERCEPTION CAPITAL CORP IV. (Exact name of registr ...

Tile of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share AMTM New York Stock Exchange UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 27, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

Exhibit 99.1 Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines - Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Buildout of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET - STONY BROOK, N.Y. – December 17, 2024 - Applied D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________ Form 10-K _____________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36334 ___ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share SONN The Nasdaq Capital Market LLC FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co ...

Exhibit 99.1 Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN) Multiple value-driving milestones expected throughout calendar year 2025 as well as pipeline expansion opportunities across the solid tumor ...

Exhibit 99.1 NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025 Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., December 17, 2024 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transfo ...

Exhibit 99.1 5,175,000 COMMON SHARES ELECTROVAYA INC. UNDERWRITING AGREEMENT December 17, 2024 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 San Clemente Dr. Newport Beach, CA 92660 Ladies and Gentlemen: The undersigned, Electrovaya Inc., a corporation existing under the laws of the Province of Ontario, Canada (the "Company"), hereby confirms its agreement (this "Agreement") with the several underwriters (s ...

Exhibit 99.1 THE CHILDREN'S PLACE REPORTS THIRD QUARTER 2024 RESULTS Reports Second Consecutive Quarter of Adjusted Profitability Significant Improvement in Gross Profit Margin to 35% Lowest Level of SG&A spending in more than 15 Years during Q3 Reports Adjusted EBITDA of $44.5 million and Adjusted EPS of $2.04 Maintains Total Liquidity of $94 Million Secaucus, New Jersey – December 3, 2024 – The Children's Place, Inc. (Nasdaq: PLCE), an omni-channel children's specialty portfolio of brands, today announced ...